Biomarkers of Cardiovascular Disease in Patients With Ankylosing Spondylitis.
Ankylosing spondylitis
arterial stiffness
cardiovascular disease
pulse wave velocity
Journal
Archives of rheumatology
ISSN: 2618-6500
Titre abrégé: Arch Rheumatol
Pays: Turkey
ID NLM: 101639000
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
20
10
2019
accepted:
30
12
2019
entrez:
18
1
2021
pubmed:
19
1
2021
medline:
19
1
2021
Statut:
epublish
Résumé
This study aims to evaluate the inflammatory status and clinical and vascular alterations using tonometry and B-mode sonography in patients with ankylosing spondylitis (AS). The study included 71 AS patients (57 males, 14 females; mean age 40.1±10.8 years; range, 29 to 51 years) without cardiovascular disease and 30 healthy controls (24 males, 6 females; mean age 41.2±9.3 years; range, 32 to 50 years). We evaluated participants' clinical, biological and functional status along with laboratory data and measured both the arterial stiffness using carotid-femoral pulse wave velocity (PWV) measured by applanation tonometry and carotid intima-media thickness (CIMT) as a preclinical atherosclerosis marker. The mean disease duration of AS patients was 10.6±4.2 years. CIMT (p=0.03) and PWV (p=0.04) data showed significant differences between AS patients and healthy controls. Multiregression analysis showed that PWV correlated with age (r This study demonstrated an increase in early preclinical atherosclerosis in AS patients without cardiovascular (CV) disease compared to healthy controls. Therefore, screening AS patients with noninvasive methods for atherosclerosis and subclinical vasculopathy would allow us to take primary prevention measures. We found that the major determinant for increased CV risk was the disease duration, while there was no difference between different treatment modalities.
Identifiants
pubmed: 33458668
doi: 10.46497/ArchRheumatol.2020.7868
pmc: PMC7788654
doi:
Types de publication
Journal Article
Langues
eng
Pagination
435-439Informations de copyright
Copyright © 2020, Turkish League Against Rheumatism.
Déclaration de conflit d'intérêts
Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
Références
J Rheumatol. 2011 Apr;38(4):723-9
pubmed: 21239756
Semin Arthritis Rheum. 2004 Dec;34(3):585-92
pubmed: 15609262
Curr Drug Targets. 2014 Apr;15(4):442-53
pubmed: 24517161
Am J Hypertens. 2005 Jan;18(1 Pt 2):3S-10S
pubmed: 15683725
Rheumatology (Oxford). 2006 Mar;45(3):283-6
pubmed: 16204374
Rheumatol Int. 2009 Oct;29(12):1435-9
pubmed: 19288264
Atherosclerosis. 2008 Mar;197(1):326-32
pubmed: 17604035
Clin Rheumatol. 2016 Aug;35(8):2017-2022
pubmed: 27169859
Clin Rheumatol. 2007 May;26(5):710-4
pubmed: 16933103
Semin Arthritis Rheum. 2008 Oct;38(2):67-70
pubmed: 18395772
Ann Rheum Dis. 2009 Mar;68(3):362-6
pubmed: 18390569
Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):281-90
pubmed: 22075248
Eur Heart J. 2006 Nov;27(21):2588-605
pubmed: 17000623
Rheumatology (Oxford). 2008 Aug;47(8):1203-7
pubmed: 18524805
Angiology. 2019 Jul;70(6):492-500
pubmed: 30497278
Joint Bone Spine. 2008 Oct;75(5):548-53
pubmed: 18487068
Arthritis Rheum. 2011 Nov;63(11):3294-304
pubmed: 21834064